In particular, a combination of an IDO1 inhibitor and a PD-1/PD-L1 inhibitor is expected to be an effective treatment option that is currently being tested in many ongoing clinical trials for patients with various solid tumors, including NSCLC [13, 14, 34–39]. Here, PDCD1 is linked to non-small cell lung carcinoma.